Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765–73.

Article  PubMed  Google Scholar 

Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 2003;29(1):33–43.

Article  PubMed  Google Scholar 

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

Article  CAS  PubMed  Google Scholar 

Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today. 2009;45(12):865–76.

Article  Google Scholar 

Hay A, Byers A, Sereno M, Basra MK, Dutta S. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015;11: CD011458.

Google Scholar 

Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicenter, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016;233:2663–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–36.

Article  CAS  PubMed  Google Scholar 

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325–39.

CAS  PubMed  PubMed Central  Google Scholar 

Pratts M, Citrome L, Grant W, Leso L, Opler LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–8.

Article  CAS  PubMed  Google Scholar 

Plosker GL, Deeks ED. Asenapine: a review in schizophrenia. CNS Drugs. 2016;30(7):655–66.

Article  CAS  PubMed  Google Scholar 

Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803–30.

CAS  PubMed  Google Scholar 

Vieta E, Montes JM. A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig. 2018;38(2):87–99.

Article  CAS  PubMed  Google Scholar 

Matsuzaki H, Hatano M, Iwata M, Yamada S. Treatment continuation of asenapine or olanzapine in Japanese schizophrenia patients: a propensity score matched study. Neuropsychiatr Dis Treat. 2021;17:3655–61.

Article  PubMed  PubMed Central  Google Scholar 

Kinoshita T, Won K, Tamura F, Sasagawa Y. Long-term study of asenapine in subjects with residual subtype, receiving multiple or/and high dose drugs, or treatment refractory schizophrenia (Protocol P06238). Jpn J Clin Psychopharmacol. 2016;19(6):771–87.

Google Scholar 

Kinoshita T, Takekita Y, Hiraoka S, Tamura F, Iwama Y. Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: a phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication. Neuropsychopharmacol Rep. 2023;43(3):328–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kitamura Y, Kosuge N, Hiraoka S, Iwama Y, Tominaga Y, Matsui D. Evaluation of the safety and efficacy with asenapine sublingual tablets in acute clinical settings in patients with schizophrenia—final report on post-marketing surveillance study. Jpn J Clin Psychopharmacol. 2021;24(7):751–64.

Google Scholar 

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–29.

Article  PubMed  Google Scholar 

Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138–46.

Article  CAS  PubMed  Google Scholar 

Inoue Y, Suzuki H, Hibino H, Takaya A, Mikami K, Yamamoto K, et al. Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia. Brain Behav. 2021;11(5): e02109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinoshita T, Won K, Tamura F, Sasagawa Y. Long-term study of asenapine in subjects with residual subtype, receiving multiple or/and high dose drugs, or treatment refractory schizophrenia (Protocol P06238) (in Japanese). Jpn J Clin Psychopharmacol. 2016;19(6):771–87.

Google Scholar 

Yoshimura Y, Shimizu H, Yamashita R, Washida K, Takeda T, Aoki S. Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2020;35(2):98–104.

Article  PubMed  Google Scholar 

Iruretagoyena B, Castañeda CP, Mena C, Diaz C, Nachar R, Ramirez-Mahaluf JP, et al. Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia. Schizophr Res. 2021;235:102–8.

Article  CAS  PubMed  Google Scholar 

Takaesu Y, Kishimoto T, Murakoshi A, Takahashi N, Inoue Y. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: a prospective observational study. Psychiatry Res. 2016;236:71–4.

Article  CAS  PubMed  Google Scholar 

Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65–73.

Article  CAS  PubMed  Google Scholar 

Kanahara N, Kimura H, Kinoshita T, Iyo M, Takekita Y. Efficacy of asenapine in drug-resistant psychotic patients with dopamine supersensitivity psychosis: two cases. Clin Psychopharmacol Neurosci. 2023;21(1):197–201.

Article  PubMed  PubMed Central  Google Scholar 

Takao N, Murai T, Fujiwara H. Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine. BMJ Case Rep. 2021;14(4): e242495.

Article  PubMed  PubMed Central  Google Scholar 

Nakata Y, Kanahara N, Iyo M. Dopamine supersensitivity psychosis in schizophrenia: concepts and implications in clinical practice. J Psychopharmacol. 2017;31(12):1511–8.

Article  CAS  PubMed  Google Scholar 

Liu J, Cattaneo C, Papavasileiou M, Methven L, Bredie WLP. A review on oral tactile sensitivity: measurement techniques, influencing factors and its relation to food perception and preference. Food Qual Prefer. 2022;100:104624.

Article  Google Scholar 

Frank ME, Hettinger TP, Mott AE. The sense of taste: neurobiology, aging, and medication effects. Crit Rev Oral Biol Med. 1992;3(4):371–93.

Article  CAS  PubMed  Google Scholar 

Bangcuyo RG, Simons CT. Lingual tactile sensitivity: effect of age group, sex, and fungiform papillae density. Exp Brain Res. 2017;235(9):2679–88.

Article  PubMed  Google Scholar 

Schiffman SS. Influence of medications on taste and smell. World J Otorhinolaryngol Head Neck Surg. 2018;4(1):84–91.

Article  PubMed  PubMed Central  Google Scholar